Malignant pleural mesothelioma is a lethal cancer with a moderate response to registered
treatment. Current first-line treatment consists of a combination of platinum-based …

Malignant pleural mesothelioma is a rare and aggressive malignancy arising from
mesothelial cells that line the serous membranes of the body. Cytotoxic chemotherapy has …

Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment
of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by …

Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure.
Despite application of different modalities such as chemotherapy, radiotherapy and surgery …

Simple Summary Immune checkpoint inhibitors (ICIs) have emerged as a very promising
therapeutic option for the treatment of many difficult-to-treat cancers and a number of clinical …

The only registered systemic treatment for malignant pleural mesothelioma (MPM) is
platinum based chemotherapy combined with pemetrexed, with or without bevacizumab …

At the clinical level the role of immunotherapy in cancer is currently at a pivotal point.
Therapies such as checkpoint inhibitors are being approved at many levels in cancers such …

Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor
prognosis. For almost two decades, the world standard treatment regimen for unresectable …

Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated,
poor survival of approximately nine months from diagnosis. Until recently, phase II–III …

Malignant pleural mesothelioma (MPM) is the most common type of malignant
mesothelioma. It is a rare tumor linked to asbestos exposure and is associated with a poor …